How AI-driven insights from RWD accelerate the diagnosis and treatment of undiagnosed patients: A case study in alpha-1 antitrypsin deficiency…
Volv Global at WODC Europe 2025 - Where Technology Meets Human Volv Global sits at the crucial intersection between technology…
Volv Global CEO and Founder Christopher Rudolf will speak on optimising rare disease clinical trials with Real World Data at…
Volv Global presented two posters at ATS 2025, in collaboration with Takeda The posters were the result of work to…
Volv Global is pleased to attend Swiss Biotech Day 2025! Meet us at Messe Basel, 5th-6th May, to find out…
ÉPALINGES, Switzerland, March 5, 2025 /PRNewswire-PRWeb/ Volv Global expands office footprint to more than double its office space for…
Volv Global sits at the crucial intersection between technology and human beings, i.e., patients and physicians, supporting favourable patient journeys…
This article is also available in French and originally published 24 Heures. Read the original article Based in Épalinges, the small…
Alpha-1 antitrypsin deficiency (AATD) Alpha-1 antitrypsin deficiency (AATD) is a rare genetic condition which can cause lung disease in adults…
Volv, supported by Sanofi, and working with Optimum Patient Care, and collaborating with a specialist Consultant Clinician, is performing research…